VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF), is pleased to invite investors and other interested
VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it plans to move forward with its intravenous formulation of its AP-188 (“N,N-Dimethyltryptamine” or “DMT”) stroke research program as its lead asset, after having sold its Ifenprodil research program for USD $2M cash and a 20% common share
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U S Based Seyltx for USD $2M and a 20% Equity Position lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF) a Canadian clinical stage pharmaceutical development
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.